Ivanović V, Popović L, Kovacina K, Dimitrijević L, Ilić D, Pirozkov A, Baltić V
Institute of Nuclear Sciences Boris Kidric Vinca, Belgrade, Yugoslavia.
Acta Haematol. 1990;84(2):64-7. doi: 10.1159/000205030.
An anti-idiotypic IgG1 kappa murine monoclonal antibody (MoAb) Y7 against purified monoclonal IgM lambda 1, derived from a patient with Waldenström's macroglobulinemia, has been generated. This antibody cross-reacted with the tumor-derived idiotypes of patients with B cell non Hodgkin's lymphoma as measured by competitive inverse solid radioimmunoassay using unpurified serum samples. Our results with the inhibition curves of 10 sera of normal donors and 60 sera of lymphoma patients indicate that 21 lymphoma patients revealed cross-reactivities greater than 7%, the mean value observed in normal donors. Of these, 5 sera cross-reacted strongly, in the range of 43-163%, revealing a frequency of positive cross-reactivity for MoAb Y7 of 1/12 sera of lymphoma patients. The generation of a panel of anti-idiotypic antibodies which cross-react with different tumor-derived Ig in serum may be valuable for monitoring the disease in a high proportion of NHL patients.
已制备出一种抗独特型IgG1 κ小鼠单克隆抗体（MoAb）Y7，它针对的是从一名华氏巨球蛋白血症患者体内纯化得到的单克隆IgM λ1。通过使用未纯化血清样本的竞争性反向固相放射免疫测定法检测，该抗体与B细胞非霍奇金淋巴瘤患者肿瘤来源的独特型发生交叉反应。我们对10名正常供体血清和60名淋巴瘤患者血清的抑制曲线研究结果表明，21名淋巴瘤患者显示出大于7%的交叉反应性，这是正常供体中观察到的平均值。其中，5份血清发生强交叉反应，范围在43% - 163%，显示MoAb Y7在淋巴瘤患者血清中的阳性交叉反应频率为1/12。一组能与血清中不同肿瘤来源Ig发生交叉反应的抗独特型抗体的产生，对于监测高比例的非霍奇金淋巴瘤患者的病情可能具有重要价值。
